Discover Funding Opportunities

The Pioneer SCA3 Translational Research Award is granted annually by the National Ataxia Foundation to independent researchers for outstanding proposals that aim to make meaningful advancements in the treatment and care of individuals with Spinocerebellar Ataxia Type 3 (SCA3). While proposals may include components related to other forms of ataxia, the primary focus must be on preclinical, translational or clinical research directly relevant to SCA3. Priority is placed on proposals that accelerate the development of disease-modifying therapies, support clinical trial readiness and biomarker discovery, bridge the gap between scientific discovery and therapeutic application, and significantly advance or alter our mechanistic understanding of SCA3 pathogenesis. The award provides up to $100,000 for one year (April 1, 2026 to March 31, 2027) for direct research expenses only, with no more than 50% allocated to personnel costs and no indirect costs allowed. Proposals should demonstrate a clear path toward improving patient outcomes and advancing the field toward clinical solutions for SCA3. Interdisciplinary and collaborative projects, as well as those leveraging cutting-edge technologies or resources, are encouraged.

The Michael Lundquist Grant to Advance MSA-C Research is awarded annually by the National Ataxia Foundation to independent researchers for outstanding proposals that aim to make meaningful advancements in the treatment and care of individuals affected by multiple system atrophy, cerebellar subtype (MSA-C). While proposals may include aspects relevant to other forms of ataxia, the primary focus must be on preclinical, translational, or clinical research directly related to MSA-C. Priority is given to proposals that accelerate the development of disease-modifying therapies, support clinical trial readiness including biomarker discovery and validation, develop new or improve existing methods for accurate and timely diagnosis of MSA-C, bridge the gap between scientific discovery and therapeutic application, and significantly advance or reshape mechanistic understanding of MSA-C pathogenesis. This grant honors the legacy of Michael Lundquist and reflects NAF's commitment to advancing research that improves outcomes for people living with MSA-C.